In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS 

No. 16-848V 

(Not to be Published)

* * * * * * * * * * * * * * * * * * * *

HOLLY D. PATEL, * Filed: October 3, 2018 

* 

Petitioner, *

* Special Master Corcoran 

v. *

*

SECRETARY OF HEALTH AND *

HUMAN SERVICES, *

 *

 Respondent. *

* 

* * * * * * * * * * * * * * * * * * * * 

Andrew D. Downing, Van Cott & Talamente, PLLC, Phoenix, AZ, for Petitioner. 

Glenn MacLeod, U.S. Department of Justice, Washington, D.C., for Respondent. 

ORDER DEFERRING RESOLUTION OF RENEWED REQUEST 

FOR INTERIM AWARD OF ATTORNEY’S FEES AND COSTS1

On June 19, 2016, Holly Patel filed this action seeking compensation under the National 

Vaccine Injury Compensation Program (the “Program”).2

 Petitioner alleges that she suffers from 

chronic inflammatory demyelinating polyneuropathy (“CIDP”) as a result of an influenza (“flu”) 

vaccine administered to her in the U.K. on November 18, 2013. (She previously also alleged that 

the Repevax (diphtheria/tetanus/pertussis/polio) vaccine she received in August 2013 was 

associated with her CIDP, but has since dropped that element of her claim). 

Although this case is less than two years old, Petitioner replaced her first counsel, Mr. 

 

1 Although this Decision has been formally designated “not to be published,” it will nevertheless be posted on the Court 

of Federal Claims’ website in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012). This means 

that the Decision will be available to anyone with access to the internet. As provided by 42 U.S.C. § 300aa12(d)(4)(B), however, the parties may object to the Decision’s inclusion of certain kinds of confidential information. 

Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any 

information furnished by that party (1) that is a trade secret or commercial or financial in substance and is privileged or 

confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly 

unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole decision will be available to the public. Id. 

2The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 

Stat. 3758, codified as amended, 42 U.S.C. §§ 300aa-10 through 34 (2012) [hereinafter “The Program” or “Program”]. 

Individual section references hereafter will be to § 300aa of the Act. 
2

Franklin John Caldwell, with Mr. Andrew Downing on February 20, 2018. At that time, she 

requested an interim fee award for Mr. Caldwell, but I deferred resolution of the motion. See

Order, dated March 15, 2018 (ECF No. 31). I did so because (a) I had some initial concerns about 

the claim’s reasonable basis (in particular due to unresolved questions of whether the flu vaccine 

administered abroad was covered under the Vaccine Program), and (b) a combination of the case’s 

procedural history and the amount of costs at issue led me to conclude that an interim award was 

not appropriate. Order at 4–5.

 Petitioner has now (seven months after her first interim request) made a second, renewed 

request, seeking both the sums previously requested for Mr. Caldwell’s work as well as additional 

amounts incurred by Mr. Downing. See Renewed Motion, dated September 14, 2018 (ECF No. 51). 

In addition to the approximately $29,000.00 in fees and costs incurred by Mr. Caldwell during the 

first eighteen months of the case’s life, Petitioner also seeks an interim award of approximately 

$49,000.00, roughly half of which is attorney time with the remainder reflecting expert costs. See 

Renewed Motion at 4. Respondent has deferred resolution of the propriety of an interim award, as 

well as the reasonableness of any amount so awarded, to my discretion. See Response, dated 

September 25, 2018 (ECF No. 54), at 2–3. 

The attorney and paralegal time incurred by present counsel was billed from January of this 

year through September, or over a nine-month period. See Ex. A to Renewed Motion (ECF No. 51-

1) at 1-26. This is not a time frame I would ordinarily deem long enough to suggest a “protracted” 

case in which an interim award is appropriate, nor is the sum incurred by present counsel of the 

magnitude I deem sufficient for such a mid-case award. See Initial Order, dated July 27, 2016 (ECF 

No. 5), at 5–6. Petitioner, however, urges me to aggregate the amounts sought by both attorneys, and 

also to take into account the total amount of time that has accrued since the matter’s filing. Renewed 

Motion at 4. With respect to fees requested for the time incurred by Petitioner’s expert, Dr. Laura 

Boylan, Petitioner had provided only a single invoice page, from which it appears that Dr. Boylan 

seeks a rate of $600 per hour (although she does not break down the work performed in total on this 

matter). Ex. A at 35. 

Based on my review of the above, I find that an interim award of fees and costs is no more 

appropriate at this time than six months ago. I acknowledge that Petitioner’s narrowing of the nature 

of her claim (as well as Respondent’s apparent acceptance that the flu vaccine in question is covered 

by the Vaccine Act) alleviates some of my prior reasonable basis concerns. However, I do not find 

that the circumstances of this case and its prosecution otherwise render an interim award necessary. 

Present counsel has only been on the matter for nine months, and the fees and costs incurred to date 

are not of a magnitude that would cause me to find that an interim award is merited given the 

relatively short time that has passed since counsel changed. 

I also do not find persuasive Petitioner’s attempt to combine all fees incurred by separate 

counsel in order to increase the magnitude of sums incurred. Certainly Petitioner has not 
3

demonstrated herein that she has incurred such costs (a factor that would weigh more in favor of an 

interim award). While I do not doubt that attorneys carry burdens in representing Vaccine Act 

petitioners, and that in many circumstances those burdens can justify an interim award of fees or 

costs, it is not the case that counsel are ever entitled to such an award. As I have observed before, the 

fees provisions of the Vaccine Act exist to aid petitioners—not their counsel. See, e.g., Carda ex rel. 

G.J.C. v. Sec’y of Health & Human Servs., No. 14-191V, 2017 WL 5378364, at *2 (Fed. Cl. Spec. 

Mstr. Sept. 5, 2017). 

CONCLUSION 

For the reasons set forth above, I hereby determine than an interim fees and costs award 

remains inappropriate at this time, and I therefore again DEFER ruling on it. Petitioner may, 

however, request an interim award once this matter is scheduled for trial, at which time I will be 

prepared to act on it. 

IT IS SO ORDERED.

/s/ Brian H. Corcoran 

Brian H. Corcoran

Special Master